Join the Hidradenitis Suppurativa group to help and get support from people like you.
Hidradenitis Suppurativa News
Bimekizumab Yields Meaningful Response in Hidradenitis Suppurativa
THURSDAY, May 30, 2024 – Bimekizumab is well tolerated and produces clinically meaningful responses in patients with hidradenitis suppurativa, according to a study published online May 22 in The...
FDA Approves Simlandi (adalimumab-ryvk), an Interchangeable Biosimilar to Humira
REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 24, 2024 (GLOBE NEWSWIRE) – Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE:...
Clinical Markers Improve With IV Ertapenem for Hidradenitis Suppurativa
WEDNESDAY, Feb. 21, 2024 – Treatment of hidradenitis suppurativa (HS) with intravenous ertapenem is associated with improvement in clinical and inflammatory markers, according to a study published...
Factors ID'd That Affect Medical Decision-Making in Hidradenitis Suppurativa
WEDNESDAY, Jan. 17, 2024 – Factors that affect medical decision-making among patients with hidradenitis suppurativa (HS) include suffering threshold, perceptions of treatment risk, treatment...
FDA Approves Novartis' Cosentyx as the First New Biologic Treatment Option for Hidradenitis Suppurativa Patients in Nearly a Decade
FDA approval based on robust Phase III data in which Cosentyx® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 21 As the only IL-17A inhibitor ...
FDA Grants Interchangeable Designation to Pfizer’s Biosimilar Abrilada
NEW YORK, October 5, 2023 – Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has designated Abrilada™ (adalimumab-afzb) as an interchangeable biosimilar to Hum...
FDA Approves Yuflyma (adalimumab-aaty), a Biosimilar to Humira
JERSEY CITY, N.J.--(BUSINESS WIRE) May 24, 2023 --Celltrion USA today announced that the U.S. Food and Drug Administration (FDA) has approved Yuflyma® (adalimumab-aaty), a high-concentration ...
FDA Approves Humira (adalimumab) for Moderate to Severe Hidradenitis Suppurativa
NORTH CHICAGO, Ill., Sept. 10, 2015 /PRNewswire/ – AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Humira...
Ask a question
To post your own question to this support group, sign in or create an account.